Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Raised by Cornerstone Advisors LLC

Cornerstone Advisors LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 1.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,700 shares of the medical research company’s stock after purchasing an additional 300 shares during the period. Cornerstone Advisors LLC’s holdings in Thermo Fisher Scientific were worth $8,959,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Halpern Financial Inc. raised its position in Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after acquiring an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Live Oak Investment Partners acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $36,000. Tyler Stone Wealth Management acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $38,000. 87.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of several research analyst reports. Citigroup upped their price target on shares of Thermo Fisher Scientific from $530.00 to $575.00 and gave the company a “buy” rating in a research report on Monday, December 11th. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $660.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. Robert W. Baird reaffirmed an “outperform” rating and set a $670.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Finally, Raymond James lifted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $596.00.

Check Out Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Trading Down 0.3 %

NYSE:TMO traded down $1.76 during mid-day trading on Monday, hitting $548.99. The company had a trading volume of 504,775 shares, compared to its average volume of 1,928,136. The firm has a market cap of $212.11 billion, a P/E ratio of 35.65, a P/E/G ratio of 2.31 and a beta of 0.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $593.17. The business’s fifty day moving average is $533.33 and its two-hundred day moving average is $513.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the prior year, the company earned $5.40 EPS. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Tuesday, November 14th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.